JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300

JP Morgan analyst Chris Schott has maintained an Overweight rating on AbbVie (NYSE: ABBV) and raised the price target from $285 to $300. This adjustment reflects positive expectations for the company's performance in the market.